GT Biopharma Inc

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, has named Dr. Jeff Miller, renowned NK Cell Cancer Specialist as Consulting Chief Medical Officer.

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

BRISBANE, CALIFORNIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, will present two poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer.

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the presentation of new data at the American Society of Hematology's 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13, 2022. The presentation highlights a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining its TriKE platform and the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc.

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

BRISBANE, CALIFORNIA, Oct. 31, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced third quarter fiscal 2022 results for the period ended September 30, 2022.

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Brisbane, California--(Newsfile Corp. - October 25, 2022) - GT Biopharma, Inc.

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced two poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The two posters will highlight preclinical data on tri-specific NK cell engagers for the treatment of mesothelioma and prostate cancer.

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

- Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022

GT Biopharma Announces Adjournment of Special Shareholders Meeting

BRISBANE, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) --  GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced highlights of an accepted abstract titled, “B7H3-Targeted Tri-specific Killer Engagers deliver IL-15 to NK cells but not T cells, and specifically targets solid tumors as a pan-tumor antigen strategy mediated through NK cells,” for poster presentation both virtually at the European Society for Medical Oncology ("ESMO") Congress 2022 being held at the Paris Expo Porte de Versailles from September 9-13, in Paris, France.

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event.

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced entering into a Settlement and Investment Agreement (the “Agreement”) with its contract manufacturing partner Cytovance Biologics. The signed Agreement, covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. Food and Drug Administration (“FDA”) of its lead investigational asset GTB-3650.

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

BRISBANE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

BRISBANE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data in chronic lymphocytic leukemia (“CLL”) to be presented at the European Hematology Association (EHA) 2022 Congress. The poster presentation titled, “Second-Generation CD19 Targeting Tri-Specific Killer Engager Drives Robust NK Cell Function Against B Cell Malignancies,” presented by Dr. Jeff Miller's laboratory, University of Minnesota.

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

BRISBANE, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter fiscal 2022 results for the period ended March 31, 2022.

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo - Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO TAT Congress. Demonstrated novel B7-H3 targeting dual camelid nanobody TriKE® and GTB-5550 induce NK cell activation against broad spectrum of tumors at ESMO IO Congress 2021.

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

-          GTB-5550 TriKE significantly enhances NK cell mediated killing of myeloma cells, even in the relatively low B7-H3-expressing H929 cell line -          Preclinical data demonstrates GTB-5550 reverses MDSC-induced myeloma growth BRISBANE, Calif. , March 21, 2022 /PRNewswire/ -- GT Biopharma, Inc. ("the Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today, preclinical data to be presented at the hybrid 48th European Society for Blood and Marrow Transplantation Annual Meeting (EBMT).

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

BRISBANE, Calif., March 9, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, presented preclinical data demonstrating its novel TriKE driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO's Targeted Anticancer Therapies Congress (TAT).

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

BRISBANE, Calif. , March 3, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO, will participate in a fireside chat in-person at the 34th Annual ROTH Conference on Tuesday March 15, 2022, at 8:30 AM PT.

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE)  Abstract Number:   250 Session:    Immunotherapy Presentation Type:  Poster Session Date and Time:  March 7, 9:20AM (CET) (On-demand e-poster display)   Location:          Virtual Poster Board Number:   17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title:                  A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number:        AS-EBMT-2022-00508 Session:                       New Drugs- and Cell-Based Immune Therapies Presentation Type:      Poster Session Date and Time:  March 19, 2022, 9:50 AM (CET) Location:                        Prague Congress Center, Czech Republic Poster Board Number:  P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N.

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately.

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B.

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

BRISBANE, Calif., Jan. 6, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Compensation Committee of its Board of Directors approved, on December 31, 2021, the following equity compensation awards as inducements material to the following employees' acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4): Gavin Choy, the Company's Acting Chief Financial Officer and Chief Clinical Development Officer, received options to purchase 227,500 shares of the Company's common stock, having term of 10 years, a per share exercise price of $3.05 (the closing price of the Company's common stock as quoted on the Nasdaq Capital Market), and vesting 33% on the date of grant, 33% on the first annual anniversary of his start date, and 34% on the second annual anniversary of this start date, subject to continued service on behalf of the Company, and subject to full acceleration immediately prior to the consummation of a change of control or similar transaction.

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

BEVERLY HILLS, Calif., Dec. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the Company's mini-poster presentation abstract is now broadly available on the European Society for Medical Oncology ("ESMO") Immuno-Oncology ("IO") Congress 2021 abstracts webpage.

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

News for GT Biopharma Inc Stock (GTBP)